PRKDC and neoplasm: Indeed, combined administration of a DNA-PK inhibitor (NU7441) with olaparib and radiotherapy has been shown to inhibit tumor cell proliferation both in vivo and in vitro, further suggesting that the combination of these agents may be responsible for the inhibition of the CDK and ERK pathway-related kinases [235].